577 related articles for article (PubMed ID: 29754775)
1. In Situ Gene Therapy via AAV-CRISPR-Cas9-Mediated Targeted Gene Regulation.
Moreno AM; Fu X; Zhu J; Katrekar D; Shih YV; Marlett J; Cabotaje J; Tat J; Naughton J; Lisowski L; Varghese S; Zhang K; Mali P
Mol Ther; 2018 Jul; 26(7):1818-1827. PubMed ID: 29754775
[TBL] [Abstract][Full Text] [Related]
2. Nrl knockdown by AAV-delivered CRISPR/Cas9 prevents retinal degeneration in mice.
Yu W; Mookherjee S; Chaitankar V; Hiriyanna S; Kim JW; Brooks M; Ataeijannati Y; Sun X; Dong L; Li T; Swaroop A; Wu Z
Nat Commun; 2017 Mar; 8():14716. PubMed ID: 28291770
[TBL] [Abstract][Full Text] [Related]
3. In Vivo CRISPR/Cas9-Mediated Genome Editing Mitigates Photoreceptor Degeneration in a Mouse Model of X-Linked Retinitis Pigmentosa.
Hu S; Du J; Chen N; Jia R; Zhang J; Liu X; Yang L
Invest Ophthalmol Vis Sci; 2020 Apr; 61(4):31. PubMed ID: 32330228
[TBL] [Abstract][Full Text] [Related]
4. CRISPR/Cas9-mediated genome engineering: an adeno-associated viral (AAV) vector toolbox.
Senís E; Fatouros C; Große S; Wiedtke E; Niopek D; Mueller AK; Börner K; Grimm D
Biotechnol J; 2014 Nov; 9(11):1402-12. PubMed ID: 25186301
[TBL] [Abstract][Full Text] [Related]
5. Use of AAV Vectors for CRISPR-Mediated In Vivo Genome Editing in the Retina.
Yu W; Wu Z
Methods Mol Biol; 2019; 1950():123-139. PubMed ID: 30783971
[TBL] [Abstract][Full Text] [Related]
6. A multifunctional AAV-CRISPR-Cas9 and its host response.
Chew WL; Tabebordbar M; Cheng JK; Mali P; Wu EY; Ng AH; Zhu K; Wagers AJ; Church GM
Nat Methods; 2016 Oct; 13(10):868-74. PubMed ID: 27595405
[TBL] [Abstract][Full Text] [Related]
7. Application of CRISPR-Cas9-Mediated Genome Editing for the Treatment of Myotonic Dystrophy Type 1.
Marsh S; Hanson B; Wood MJA; Varela MA; Roberts TC
Mol Ther; 2020 Dec; 28(12):2527-2539. PubMed ID: 33171139
[TBL] [Abstract][Full Text] [Related]
8. AAV-Mediated CRISPR/Cas Gene Editing of Retinal Cells In Vivo.
Hung SS; Chrysostomou V; Li F; Lim JK; Wang JH; Powell JE; Tu L; Daniszewski M; Lo C; Wong RC; Crowston JG; Pébay A; King AE; Bui BV; Liu GS; Hewitt AW
Invest Ophthalmol Vis Sci; 2016 Jun; 57(7):3470-6. PubMed ID: 27367513
[TBL] [Abstract][Full Text] [Related]
9. Gene and mutation independent therapy via CRISPR-Cas9 mediated cellular reprogramming in rod photoreceptors.
Zhu J; Ming C; Fu X; Duan Y; Hoang DA; Rutgard J; Zhang R; Wang W; Hou R; Zhang D; Zhang E; Zhang C; Hao X; Xiong W; Zhang K
Cell Res; 2017 Jun; 27(6):830-833. PubMed ID: 28429769
[No Abstract] [Full Text] [Related]
10. CRISPR Systems Suitable for Single AAV Vector Delivery.
Stevanovic M; Piotter E; McClements ME; MacLaren RE
Curr Gene Ther; 2022; 22(1):1-14. PubMed ID: 34620062
[TBL] [Abstract][Full Text] [Related]
11. Gene Therapy with CRISPR/Cas9 Coming to Age for HIV Cure.
Soriano V
AIDS Rev; 2017; 19(3):167-172. PubMed ID: 29019352
[TBL] [Abstract][Full Text] [Related]
12. AAV mediated genome engineering with a bypass coagulation factor alleviates the bleeding phenotype in a murine model of hemophilia B.
Sarangi P; Kumar N; Sambasivan R; Ramalingam S; Amit S; Chandra D; Jayandharan GR
Thromb Res; 2024 Jun; 238():151-160. PubMed ID: 38718473
[TBL] [Abstract][Full Text] [Related]
13. CRISPR-Based Genome Editing as a New Therapeutic Tool in Retinal Diseases.
Rasoulinejad SA; Maroufi F
Mol Biotechnol; 2021 Sep; 63(9):768-779. PubMed ID: 34057656
[TBL] [Abstract][Full Text] [Related]
14. CRISPR-Cas9 for cancer therapy: Opportunities and challenges.
Chen M; Mao A; Xu M; Weng Q; Mao J; Ji J
Cancer Lett; 2019 Apr; 447():48-55. PubMed ID: 30684591
[TBL] [Abstract][Full Text] [Related]
15. Methods for In Vivo CRISPR/Cas Editing of the Adult Murine Retina.
Hung SS; Li F; Wang JH; King AE; Bui BV; Liu GS; Hewitt AW
Methods Mol Biol; 2018; 1715():113-133. PubMed ID: 29188510
[TBL] [Abstract][Full Text] [Related]
16. CRISPR/Cas9 technology as a potent molecular tool for gene therapy.
Karimian A; Azizian K; Parsian H; Rafieian S; Shafiei-Irannejad V; Kheyrollah M; Yousefi M; Majidinia M; Yousefi B
J Cell Physiol; 2019 Aug; 234(8):12267-12277. PubMed ID: 30697727
[TBL] [Abstract][Full Text] [Related]
17. Allele-Specific Knockout by CRISPR/Cas to Treat Autosomal Dominant Retinitis Pigmentosa Caused by the G56R Mutation in NR2E3.
Diakatou M; Dubois G; Erkilic N; Sanjurjo-Soriano C; Meunier I; Kalatzis V
Int J Mol Sci; 2021 Mar; 22(5):. PubMed ID: 33807610
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic In Vivo Gene Editing Achieved by a Hypercompact CRISPR-Cas12f1 System Delivered with All-in-One Adeno-Associated Virus.
Cui T; Cai B; Tian Y; Liu X; Liang C; Gao Q; Li B; Ding Y; Li R; Zhou Q; Li W; Teng F
Adv Sci (Weinh); 2024 May; 11(19):e2308095. PubMed ID: 38408137
[TBL] [Abstract][Full Text] [Related]
19. CRISPR/Cas9-mediated genome editing via postnatal administration of AAV vector cures haemophilia B mice.
Ohmori T; Nagao Y; Mizukami H; Sakata A; Muramatsu SI; Ozawa K; Tominaga SI; Hanazono Y; Nishimura S; Nureki O; Sakata Y
Sci Rep; 2017 Jun; 7(1):4159. PubMed ID: 28646206
[TBL] [Abstract][Full Text] [Related]
20. Selection and Validation of Spacer Sequences for CRISPR-Cas9 Genome Editing and Transcription Regulation in Bacteria.
Grenier F; Lucier JF; Rodrigue S
Methods Mol Biol; 2015; 1334():233-44. PubMed ID: 26404154
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
